On June 19-21, CPHI China, sponsored by Informa Markets and China Chamber of Commerce for Import and Export of Pharmaceutical and Health Products and co-organized by Shanghai Bohua International Exhibition Co., Ltd. was held at Shanghai New International Expo Center. The exhibition covers pharmaceutical raw materials, natural extracts, biopharmaceuticals, preparations and other fields, attracting nearly 3,500 exhibitors and more than 90,000 professionals at home and abroad.

From May 7 to 9, CPHI North America was held at the Pennsylvania Convention Center in Philadelphia, USA. As the wor

Recently, Yangpu Jingtai Pharmaceutical, a wholly-owned subsidiary of Weixinkang, received the "Drug Registration Certificate" for potassium aspartate injection approved and issued by the State Drug Administration (drug approval number: National Drug Approval number H20243591). At present, the company has begun to prepare for the listing.

From October 24 to 26, CPHI Worldwide 2023 was grandly launched in Barcelona Convention and Exhibition Center, Spain. Weixinkang brought many core products in the field of apis and preparations to the CPHI exhibition. Keep up with industry trends and continue to expand international cooperation

Recently, Xizang Zhongwei Chengkang Pharmaceutical Co., LTD., a wholly-owned subsidiary of Weixinkang Pharmaceutical, received the Drug Registration Certificate of multivitamin injection (13) (10/3) approved and issued by the State Drug Administration (drug approval number: Sinofin H20234276). According to the relevant national policies and regulations, the acquisition of the "Drug Registration Certificate" is regarded as passing the consistency evaluation.

On July 12-14, CPHI South East Asia 2023 was held at the Queen Sirikit National Convention Center in Bangkok, Thailand. Weixinkang brought core products in the field of apis and preparations to the exhibition, sharing new ideas with exhibitors and customers around the world, seeking new cooperation in the development of pharmaceutical foreign trade, and going to a new journey of internationalization.

Dopamine hydrochloride injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin sepsis, cardiac operation, renal failure, congestive heart failure, etc. Shock can not be corrected after blood volume supplementation, especially oliguria and normal or low peripheral vascular resistance shock. Since this product can increase cardiac output, it is also used for cardiac insufficiency where digitalis and diuretics do not work. Dopamine hydrochloride injection belongs to the "National Basic Medical Insurance, Industrial injury insurance and maternity Insurance drug Catalogue (2022)" class A drugs, "National Essential Drugs Catalogue (2018 edition)" drugs. The reference preparation for this variety is INOVAN® injection, marketed by Concorde 発 Yeast キリン Co., Ltd. in 2.5ml:50mg, 5ml:100mg.

The 21st CPHI China 2023, organized by Informa Markets and China Chamber of Commerce for Import and Export of Pharmaceuticals and Healthcare Products and co-organized by Shanghai UBM Sinoexpo, was held at Shanghai Pudong New International Expo Centre from 19 to 21 June. Weixin Kang Pharmaceuticals made a splendid appearance at this year's CPHI, showcasing its core products in the field of APIs and formulations, and discussing cooperation and development with customers from all over the world.